Propanc Biopharma Debt-to-Assets Ratio Growth & History (PPCB)

Propanc Biopharma's debt-to-assets ratio was 0.03 for fiscal 2025.

View full Propanc Biopharma company overview

Propanc Biopharma annual debt-to-assets ratio history

Propanc Biopharma annual debt-to-assets ratio

Fiscal yearPeriod endedDebt-to-assets ratioChangeGrowth
20252025-06-300.03−5.49−99.45%
20242024-06-305.52−0.96−14.76%
20232023-06-306.47−5.64−46.57%
20222022-06-3012.12−35.56−74.58%
20212021-06-3047.6731.61+196.74%
20202020-06-3016.07−0.24−1.46%
20192019-06-3016.30−49.52−75.23%
20182018-06-3065.8329.23+79.84%
20172017-06-3036.6033.43+1054.06%
20162016-06-303.173.17
20152015-06-300.000.00
20142014-06-300.00

Propanc Biopharma debt-to-assets ratio trends

Over the last five fiscal years, Propanc Biopharma's debt-to-assets ratio decreased from 16.07 to 0.03, a change of −16.04. The latest reported quarter, Q3 2026, shows 0.01.

About the metric

What the debt-to-assets ratio means

The debt-to-assets ratio shows the portion of a company’s reported assets financed with interest-bearing debt. It is a leverage measure and should not be confused with total liabilities divided by assets.

Calculation and source

How debt-to-assets is calculated

TickerStat calculates debt-to-assets as total interest-bearing debt divided by total assets at the same reporting-period end. Periods with missing debt or non-positive assets are omitted. Fiscal periods can differ from calendar years, so exact period-end dates are included.

Review Propanc Biopharma source filings ↗

Community posts

It’s quiet here.

No posts about PPCB yet. Start the conversation.

Write the first post